<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634877</url>
  </required_header>
  <id_info>
    <org_study_id>3475-B21</org_study_id>
    <secondary_id>KEYNOTE-B21</secondary_id>
    <secondary_id>ENGOT-en11</secondary_id>
    <secondary_id>GOG-3053</secondary_id>
    <secondary_id>2020-003424-17</secondary_id>
    <secondary_id>jRCT2031200399</secondary_id>
    <nct_id>NCT04634877</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Network for Gynaecological Oncological Trial Groups</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo +&#xD;
      adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival&#xD;
      (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of&#xD;
      suspected disease recurrence, and with respect to overall survival (OS). The primary&#xD;
      hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant&#xD;
      chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically&#xD;
      by the investigator or by histopathologic confirmation of suspected disease recurrence, and&#xD;
      with respect to OS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2021</start_date>
  <completion_date type="Anticipated">June 18, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 18, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence</measure>
    <time_frame>Up to approximately 42 months</time_frame>
    <description>DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence, will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 54 months</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS) as Assessed Radiographically by Blinded Independent Central Review (BICR) or by Histopathologic Confirmation of Suspected Disease Recurrence</measure>
    <time_frame>Up to approximately 42 months</time_frame>
    <description>DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by BICR or by histopathologic confirmation of suspected disease recurrence, will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Combined Positivity Score (CPS)-Determined Programmed Cell Death 1 Ligand 1 (PD-L1) Status</measure>
    <time_frame>Up to approximately 42 months</time_frame>
    <description>DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by CPS-determined PD-L1 status will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Combined Positivity Score (CPS)-Determined Programmed Cell Death 1 Ligand 1 (PD-L1) Status</measure>
    <time_frame>Up to approximately 54 months</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause. The OS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by CPS-determined PD-L1 status will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Tumor Mutation Burden (TMB) Status</measure>
    <time_frame>Up to approximately 42 months</time_frame>
    <description>DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by tumor mutation burden (TMB) status, will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Tumor Mutation Burden (TMB) Status</measure>
    <time_frame>Up to approximately 54 months</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause. The OS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by tumor mutation burden (TMB) status will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience One or More Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 54 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 52 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (QoL) Score</measure>
    <time_frame>Baseline and up to approximately 54 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. Participant responses to questions 29 (&quot;How would you rate your overall health during the past week?&quot;) and 30 (&quot;How would you rate your overall quality of life during the past week?&quot;) are scored on a 7-point scale (1= Very poor to 7=Excellent). A higher score indicates a better overall health/quality of life status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined scores will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Function Score</measure>
    <time_frame>Baseline and up to approximately 54 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=not at all to 4=very much). A higher score indicates a better quality of life. The change from baseline in physical function (EORTC QLQ-C30 Items 1-5) score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Endometrial Cancer (EORTC QLQ-EN24) Score</measure>
    <time_frame>Baseline and up to approximately 54 months</time_frame>
    <description>The EORTC-QLQ-EN24 is a 24-item questionnaire developed to be used in conjunction with the EORTC-QLQ-C30 to assess the quality of life of endometrial cancer patients. Participant responses are scored on a 4-point scale (1=not at all to 4=very much). A higher score indicates a better quality of life. The change from baseline in EORTC QLQ-E24 score will be presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">990</enrollment>
  <condition>Endometrial Neoplasms</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo to pembrolizumab intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of placebo, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab + Chemotherapy</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab + Chemotherapy</arm_group_label>
    <arm_group_label>Placebo + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab + Chemotherapy</arm_group_label>
    <arm_group_label>Placebo + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>IV infusion docetaxel 75 mg/m^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.</description>
    <arm_group_label>Pembrolizumab + Chemotherapy</arm_group_label>
    <arm_group_label>Placebo + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 75 mg/m^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.</description>
    <arm_group_label>Pembrolizumab + Chemotherapy</arm_group_label>
    <arm_group_label>Placebo + Chemotherapy</arm_group_label>
    <other_name>Platinol®</other_name>
    <other_name>Platinol®-AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiotherapy (EBRT)</intervention_name>
    <description>≥4500 cGY given according to local practice, at the discretion of the investigator</description>
    <arm_group_label>Pembrolizumab + Chemotherapy</arm_group_label>
    <arm_group_label>Placebo + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (as radiosensitizer)</intervention_name>
    <description>If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29</description>
    <arm_group_label>Pembrolizumab + Chemotherapy</arm_group_label>
    <arm_group_label>Placebo + Chemotherapy</arm_group_label>
    <other_name>Platinol®</other_name>
    <other_name>Platinol®-AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy</intervention_name>
    <description>Given according to local practice, at the discretion of the investigator</description>
    <arm_group_label>Pembrolizumab + Chemotherapy</arm_group_label>
    <arm_group_label>Placebo + Chemotherapy</arm_group_label>
    <other_name>Internal radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a histologically confirmed new diagnosis of Endometrial Carcinoma or&#xD;
             Carcinosarcoma (Mixed Mullerian Tumor) and:&#xD;
&#xD;
               -  Has undergone curative intent surgery that included hysterectomy and bilateral&#xD;
                  salpingo-oophorectomy; and&#xD;
&#xD;
               -  Is at high risk for recurrence following treatment with curative intent surgery,&#xD;
                  ie: Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) 2009&#xD;
                  surgical stage I/II with myometrial invasion of non-endometrioid histology; FIGO&#xD;
                  2009 surgical stage I/II with myometrial invasion of any histology with known&#xD;
                  aberrant p53 expression or p53 mutation; or FIGO (2009) surgical stage III or IVA&#xD;
                  of any histology.&#xD;
&#xD;
          -  Is disease-free with no evidence of loco-regional disease or distant metastasis post&#xD;
             operatively and on imaging.&#xD;
&#xD;
          -  Has not received any radiation or systemic therapy, including immunotherapy, hormonal&#xD;
             therapy, or hyperthermic intraperitoneal chemotherapy (HIPEC), in any setting&#xD;
             including the neoadjuvant setting for endometrial cancer (EC).&#xD;
&#xD;
          -  Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7&#xD;
             days before randomization.&#xD;
&#xD;
          -  Submission of a tumor tissue sample from current diagnosis of Endometrial Carcinoma or&#xD;
             Carcinosarcoma for prospective determination of histology and mismatch repair (MMR)&#xD;
             status by central vendor is required for all participants.&#xD;
&#xD;
          -  Has adequate organ function within 7 days of randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has recurrent endometrial carcinoma or carcinosarcoma.&#xD;
&#xD;
          -  Has uterine mesenchymal tumor such as an endometrial stromal sarcoma, leiomyosarcoma,&#xD;
             or other types of pure sarcomas. Adenosarcomas are also not allowed.&#xD;
&#xD;
          -  Has FIGO (2009) Surgical Stage I/II EC of endometrioid histology without a known&#xD;
             aberrant p53 expression or p53 mutation.&#xD;
&#xD;
          -  Is known to have a deoxyribonucleic acid (DNA) polymerase epsilon catalytic subunit A&#xD;
             (POLE) mutation.&#xD;
&#xD;
          -  Has FIGO Stage IVB disease of any histology even if there is no evidence of disease&#xD;
             after surgery.&#xD;
&#xD;
          -  Has residual tumor whether measurable or non-measurable after surgery.&#xD;
&#xD;
          -  Has a history of a second malignancy, unless potentially curative treatment has been&#xD;
             completed with no evidence of malignancy for 3 years.&#xD;
&#xD;
               -  Note: The time requirement does not apply to participants who underwent&#xD;
                  successful definitive resection of basal cell carcinoma of the skin, squamous&#xD;
                  cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer,&#xD;
                  or other in situ cancers.&#xD;
&#xD;
          -  Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1),&#xD;
             anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death&#xD;
             receptor ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or&#xD;
             co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4&#xD;
             (CTLA-4), OX-40, CD137).&#xD;
&#xD;
          -  Has received a live vaccine within 30 days before the first dose of study&#xD;
             intervention.&#xD;
&#xD;
               -  Note: killed vaccines are allowed.&#xD;
&#xD;
          -  Has a known intolerance to study intervention (or any of the excipients).&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks before the first dose of&#xD;
             study intervention.&#xD;
&#xD;
               -  Note: Participants who have entered the follow-up phase of an investigational&#xD;
                  study may participate as long as it has been 4 weeks after the last dose of the&#xD;
                  previous investigational agent.&#xD;
&#xD;
          -  Has any contraindication to the use of carboplatin or paclitaxel.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of&#xD;
             immunosuppressive therapy within 7 days prior the first dose of study intervention.&#xD;
&#xD;
          -  Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in past 2 years&#xD;
             (ie, with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency) is not considered a form&#xD;
             of systemic treatment and is allowed.&#xD;
&#xD;
          -  Has a history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy.&#xD;
&#xD;
          -  Has a known history of HIV infection.&#xD;
&#xD;
          -  Has a known history of Hepatitis B or known active Hepatitis C virus infection.&#xD;
&#xD;
          -  Has a known psychiatric or substance abuse disorder that would interfere with the&#xD;
             participant's ability to cooperate with the requirements of the study.&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant.&#xD;
&#xD;
          -  Has not recovered adequately from surgery and/or any complications from the surgery.&#xD;
&#xD;
          -  Is breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama - Birmingham ( Site 3061)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>205-934-3411</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Alabama, Mitchell Cancer Institute ( Site 3058)</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>251-665-8000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC- HAL ( Site 3043)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>602-277-4868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates PC- HOPE ( Site 3049)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>520-886-0206</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Colorado ( Site 3051)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>720-848-0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale New Haven ( Site 3070)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>203-785-6398</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northside Hospital ( Site 3036)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-851-8000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parkview Cancer Institute ( Site 3067)</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>833-724-8326</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center ( Site 3071)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>888-600-4822</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital and Clinics ( Site 3046)</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>800-237-1225</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute - St. Matthews ( Site 3056)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>502-899-3366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>WK Physicians Network/Gynecologic Oncology Associates ( Site 3047)</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>111-111-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center ( Site 3065)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>718-405-8086</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 3076)</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-731-6455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 3042)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-731-6455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 3080)</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>111-111-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OSU Wexner Medical Center ( Site 3066)</name>
      <address>
        <city>Hilliard</city>
        <state>Ohio</state>
        <zip>43026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>614-293-3873</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Legacy Good Samaritan Medical Center ( Site 3033)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>503-413-8199</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AHN West Penn Hospital ( Site 3060)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>412-578-4517</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Gynecology Oncology ( Site 3045)</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>605-312-3250</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>VCU Massey Cancer Center ( Site 3068)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>804-628-7022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 1006)</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1012AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541150319725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas Mar del Plata ( Site 1003)</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>92235937663</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico de Buenos Aires ( Site 1002)</name>
      <address>
        <city>Buenos Aires</city>
        <state>Caba</state>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541143096897</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncologia de Rosario ( Site 1004)</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000KZE</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+543414400617</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Aleman ( Site 1001)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1118AAT</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+54114827700x2306</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEMIC ( Site 1009)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1431FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541152990100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Riojano Integral ( Site 1007)</name>
      <address>
        <city>La Rioja</city>
        <zip>F5300COE</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+543804425438</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Innsbruck ( Site 2001)</name>
      <address>
        <city>Innsbruck</city>
        <state>Burgenland</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+435050422345</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Graz ( Site 2004)</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4331638581082</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.I.U. Hopital Ambroise Pare ( Site 2039)</name>
      <address>
        <city>Mons</city>
        <state>Hainaut</state>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3265414000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR Verviers ( Site 2035)</name>
      <address>
        <city>Verviers</city>
        <state>Liege</state>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3287219483</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OLV Ziekenhuis ( Site 2038)</name>
      <address>
        <city>Aalst</city>
        <state>Oost-Vlaanderen</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3253724111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares Gent ( Site 2032)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+32 9 246 46 46</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent ( Site 2037)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3293322692</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas ( Site 2031)</name>
      <address>
        <city>Sint-Niklaas</city>
        <state>Oost-Vlaanderen</state>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27118830900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven ( Site 2040)</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3216344634</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge ( Site 2036)</name>
      <address>
        <city>Kortrijk</city>
        <state>West-Vlaanderen</state>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3256633900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHC - Groupe Sante ( Site 2041)</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+32 4 355 50 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Liege Sart-Tilman ( Site 2044)</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+32 4 366 74 48</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre ( Site 3007)</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>403-521-3721</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l Universite de Montreal - CHUM ( Site 3006)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514-890-8000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre ( Site 3005)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514-934-1934</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Investigación del Cáncer James Lind ( Site 1061)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4780000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5620452982404</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Arturo Lopez Perez FALP ( Site 1062)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>7500921</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>56227067539</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Cancer Nuestra Senora de la Esperanza ( Site 1063)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8330032</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56223547919</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bradfordhill-Clinical Area ( Site 1070)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+569 9874 4662</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncocentro ( Site 1065)</name>
      <address>
        <city>Vina del Mar</city>
        <state>Valparaiso</state>
        <zip>2520598</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+569 9236 9820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital ( Site 4048)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613641356816</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital ( Site 4036)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613910217876</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital ( Site 4040)</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8618908384529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital ( Site 4043)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613602834127</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospital ( Site 4049)</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8615278015900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital ( Site 4059)</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8618971650655</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital ( Site 4037)</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>15996232819</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Maternal and Child Health Hospital ( Site 4051)</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86079186224432</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University ( Site 4057)</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0431-88786014</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Obstetrics and Gynecology Hosp. Fudan University ( Site 4041)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200090</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8673185792836</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Renji Hospital Affiliated to Jiao Tong University ( Site 4053)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613701642665</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 4001)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201204</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>021-20261234</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital ( Site 4039)</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8618908178800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women s Hospital School of Medicine Zhejiang University ( Site 4032)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>86057187061501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University ( Site 4056)</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>021-20261186</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Colombiana de Cancerologia Clinica Vida ( Site 1096)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050030</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5713102013510</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerología E.S.E ( Site 1094)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>111511</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5713102013510</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Cancerologico de Narino Ltda ( Site 1092)</name>
      <address>
        <city>San Juan De Pasto</city>
        <state>Narino</state>
        <zip>520002</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>573155831205</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 1093)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573012895296</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze ( Site 2391)</name>
      <address>
        <city>Praha</city>
        <state>Benesov</state>
        <zip>120 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420224967451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Brno Bohunice ( Site 2394)</name>
      <address>
        <city>Brno</city>
        <state>Brno-mesto</state>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420532233843</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Kralovske Vinohrady ( Site 2393)</name>
      <address>
        <city>Praha</city>
        <state>Praha 10</state>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420 267 162 368</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc ( Site 2392)</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420588444288</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet University Hospital ( Site 2515)</name>
      <address>
        <city>Copehagen</city>
        <state>Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4535453545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital ( Site 2514)</name>
      <address>
        <city>Herlev</city>
        <state>Hovedstaden</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+45 38683868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aalborg Universitetshospital ( Site 2511)</name>
      <address>
        <city>Aalborg</city>
        <state>Nordjylland</state>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4597660000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roskilde Sygehus ( Site 2513)</name>
      <address>
        <city>Roskilde</city>
        <state>Sjaelland</state>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+45 46323200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital ( Site 2512)</name>
      <address>
        <city>Odense</city>
        <state>Syddanmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4566113333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital ( Site 2541)</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35840 848 4029</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital ( Site 2543)</name>
      <address>
        <city>Kuopio</city>
        <state>Pohjois-Savo</state>
        <zip>70029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358447172330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital ( Site 2542)</name>
      <address>
        <city>Turku</city>
        <state>Varsinais-Suomi</state>
        <zip>20760</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+348405465398</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne ( Site 2073)</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33492031353</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse ( Site 2062)</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0231455002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Des Côtes d'Armor ( Site 2063)</name>
      <address>
        <city>Plérin</city>
        <state>Cotes-d Armor</state>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33296752216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Besancon - Hopital Jean Minjoz ( Site 2068)</name>
      <address>
        <city>Besancon</city>
        <state>Doubs</state>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33381218605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie ( Site 2067)</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33556333333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse - Oncopole ( Site 2065)</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33531155829</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Regional du Cancer de Montpellier - ICM ( Site 2069)</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33467613063</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin ( Site 2070)</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33158411927</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital prive du Confluent ( Site 2061)</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33228272171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut De Cancerologie De Lorraine ( Site 2072)</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33383598363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud ( Site 2064)</name>
      <address>
        <city>Pierre Benite</city>
        <state>Rhone</state>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33478864324</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy ( Site 2071)</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33 (0)1 42 11 67 78</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Patras. St Andrews ( Site 2421)</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>263 32</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+302610 227134</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Perifereiako Geniko Nosokomeio ALEXANDRA ( Site 2425)</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>115 28</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+302132162513</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 2307)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247773872</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Edith Wolfson Medical Center ( Site 2306)</name>
      <address>
        <city>Holon</city>
        <zip>5822012</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>97235028795</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center. Ein Kerem ( Site 2303)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972508946244</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 2305)</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239377594</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center ( Site 2301)</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235303157</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istittuto Nazionale dei Tumori Regina Elena IRCCS - IFO ( Site 2121)</name>
      <address>
        <city>Roma</city>
        <state>Abruzzo</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0652666919</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli ( Site 2124)</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00390630158545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto di Candiolo - IRCCS ( Site 2125)</name>
      <address>
        <city>Candiolo</city>
        <state>Piemonte</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390119933268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili di Brescia ( Site 2135)</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390303998428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele ( Site 2130)</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00390226432653</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 2122)</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390223902719</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II ( Site 2123)</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390817463660</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 2127)</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390815903637</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital ( Site 4190)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-52-762-6111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East ( Site 4197)</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-4-7133-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center ( Site 4181)</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-89-999-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital ( Site 4187)</name>
      <address>
        <city>Toon</city>
        <state>Ehime</state>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-89-964-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital ( Site 4186)</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-942-35-3311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gunma Prefectural Cancer Center ( Site 4183)</name>
      <address>
        <city>Ota</city>
        <state>Gunma</state>
        <zip>373-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-276-38-0771</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital ( Site 4194)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-11-716-1161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center ( Site 4195)</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-78-929-1151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital ( Site 4189)</name>
      <address>
        <city>Shiwa-gun</city>
        <state>Iwate</state>
        <zip>028-3695</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-19-613-7111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of the Ryukyus Hospital ( Site 4184)</name>
      <address>
        <city>Nakagami-gun</city>
        <state>Okinawa</state>
        <zip>903-0215</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-98-895-3331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University International Medical Center ( Site 4182)</name>
      <address>
        <city>Hidaka</city>
        <state>Saitama</state>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-42-984-4111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center Hospital and Research Institute ( Site 4192)</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-55-989-5222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center ( Site 4193)</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-92-541-3231</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital ( Site 4185)</name>
      <address>
        <city>Niigata</city>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-25-266-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute ( Site 4188)</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6945-1181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR ( Site 4196)</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3520-0111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital ( Site 4191)</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3353-1211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center ( Site 4065)</name>
      <address>
        <city>Goyang-si</city>
        <state>Kyonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8215888119</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 4063)</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-31-787-7253</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 4062)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82222281961</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 4061)</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-2-3010-3640</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 4064)</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-2-3410-3513</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway ( Site 2153)</name>
      <address>
        <city>Tromso</city>
        <state>Troms</state>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4777754339</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soerlandet sykehus HF Kristiansand ( Site 2152)</name>
      <address>
        <city>Kristiansand</city>
        <state>Vest-Agder</state>
        <zip>4615</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4738073070</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus Radiumhospitalet ( Site 2151)</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+22934000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im Ks Anny Mazowieckiej ( Site 2481)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>00-315</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48225966512</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bialostockie Centrum Onkologii ( Site 2483)</name>
      <address>
        <city>Bialystok</city>
        <state>Podlaskie</state>
        <zip>15-027</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0048856646728</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2482)</name>
      <address>
        <city>Gliwice</city>
        <state>Slaskie</state>
        <zip>44-102</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0048609124607</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swietokrzyskie Centrum Onkologii SPZOZ ( Site 2485)</name>
      <address>
        <city>Kielce</city>
        <state>Swietokrzyskie</state>
        <zip>25-734</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48413674128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPZOZ MSWIA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie ( Site 2486)</name>
      <address>
        <city>Olsztyn</city>
        <state>Warminsko-mazurskie</state>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0048895398078</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wielkopolskie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 2484)</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>61-866</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48618850588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Clinical Oncological Dispensary ( Site 2637)</name>
      <address>
        <city>Arkhangelsk</city>
        <state>Arkhangel Skaya Oblast</state>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78182625797</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 2645)</name>
      <address>
        <city>Ufa</city>
        <state>Baskortostan, Respublika</state>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79050022295</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clinical Center Oncology and Nuclear Medicine ( Site 2644)</name>
      <address>
        <city>Chelyabinsk</city>
        <state>Chelyabinskaya Oblast</state>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+73512328483</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Regional Clinical oncology dispensary ( Site 2643)</name>
      <address>
        <city>Krasnoyarsk</city>
        <state>Krasnoyarskiy Kray</state>
        <zip>660133</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+73912224030</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Ogarev Mordovia State University ( Site 2648)</name>
      <address>
        <city>Saransk</city>
        <state>Mordoviya, Respublika</state>
        <zip>430032</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>79271815631</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBI National Medical Oncology Research Center n.a. N.N. Blokhina ( Site 2634)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79036787205</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samara Regional Clinical Oncology Center-Chemotherapy Dapartment ( Site 2649)</name>
      <address>
        <city>Samara</city>
        <state>Samarskaya Oblast</state>
        <zip>443031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8(846)994-76-50</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 2636)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78124399507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 2646)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79172662851</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 2641)</name>
      <address>
        <city>Yaroslavl</city>
        <state>Yaroslavskaya Oblast</state>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+7 4852 208 103 ext 35</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Josep Trueta ( Site 2184)</name>
      <address>
        <city>Girona</city>
        <state>Gerona</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 97222 5828</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra ( Site 2181)</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913531920</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall D Hebron ( Site 2182)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934892658</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial ( Site 2185)</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932275400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia ( Site 2183)</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34957011456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos ( Site 2187)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913303000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 2186)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 917277516</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset i Linkoping. ( Site 2222)</name>
      <address>
        <city>Linkoping</city>
        <state>Ostergotlands Lan</state>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46101032816</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Solna ( Site 2220)</name>
      <address>
        <city>Solna</city>
        <state>Stockholms Lan</state>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0046851770000 /</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blod-och Tumorsjukdomar ( Site 2221)</name>
      <address>
        <city>Uppsala</city>
        <state>Uppsala Lan</state>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0046186170424</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital ( Site 4095)</name>
      <address>
        <city>Changhua</city>
        <zip>50006</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88647000626</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital ( Site 4094)</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886423592525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MacKay Memorial Hospital ( Site 4092)</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886225433535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital ( Site 4093)</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886228757566</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital ( Site 4091)</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886-975-365883</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baskent Adana Dr Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 2355)</name>
      <address>
        <city>Adana</city>
        <zip>01250</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903223444444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cukurova Uni. Tip Fakultesi ( Site 2353)</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903224554444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baskent Universitesi Ankara Hastanesi ( Site 2354)</name>
      <address>
        <city>Ankara</city>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903122036868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara Universitesi Tıp Fakultesi Hastanesi ( Site 2350)</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+90(312)5956000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medipol Universite Hastanesi ( Site 2352)</name>
      <address>
        <city>Istanbul</city>
        <zip>34214</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905325280486</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty ( Site 2351)</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902323902359</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Park Izmir Hastanesi ( Site 2356)</name>
      <address>
        <city>Izmir</city>
        <zip>35575</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902323995050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chernihiv Medical Center of Modern Oncology ( Site 2368)</name>
      <address>
        <city>Chernihiv</city>
        <state>Chernihivska Oblast</state>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380507058899</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Enterprise &quot;Bukovinian сlinical oncology сenter&quot; ( Site 2366)</name>
      <address>
        <city>Chernivtsi</city>
        <state>Chernivetska Oblast</state>
        <zip>58013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>380955077568</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SO Grigoriev Institute for Medical Radiology and Oncology of NAMS of Ukraine ( Site 2363)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>380958816458</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MNE &quot;Khmelnytskyi regional antitumor center&quot; ( Site 2365)</name>
      <address>
        <city>Khmelnitskyi</city>
        <state>Khmelnytska Oblast</state>
        <zip>29009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380979242755</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LISOD - Israeli Oncological Hospital MedX-ray International Group, LLC ( Site 2364)</name>
      <address>
        <city>Kiev</city>
        <state>Kyivska Oblast</state>
        <zip>08720</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380506362519</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lviv State Regional Oncological Center ( Site 2361)</name>
      <address>
        <city>Lviv</city>
        <state>Lvivska Oblast</state>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>380677479407</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Municipal Enterprise Volyn Regional Medical Oncology Centre ( Site 2362)</name>
      <address>
        <city>Lutsk</city>
        <state>Volynska Oblast</state>
        <zip>43018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503782998</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital-Academic Oncology ( Site 2252)</name>
      <address>
        <city>Cottingham</city>
        <state>East Riding Of Yorkshire</state>
        <zip>HU165JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>01482 461301</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital NHS Foundation Trust ( Site 2243)</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441614463391</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD1, PD-1)</keyword>
  <keyword>Programmed Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <keyword>Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2 )</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

